Market Place
Sourcing Support
Qualigen Announces $4.5M Private Placement of Preferred Shares
19 Nov 2024 //
GLOBENEWSWIRE
Shares to Begin Trading on Split-Adjusted Basis on Nov 5, 2024
01 Nov 2024 //
GLOBENEWSWIRE
Qualigen Therapeutics, Inc. Announces management changes.
26 Sep 2024 //
GLOBENEWSWIRE
Qualigen Received Extension from Nasdaq
20 Sep 2024 //
GLOBENEWSWIRE
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering
06 Sep 2024 //
GLOBENEWSWIRE
Qualigen Therapeutics Announces $3.46 Million Public Offering
05 Sep 2024 //
GLOBENEWSWIRE
Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination
30 May 2024 //
GLOBENEWSWIRE
Marizyme and Qualigen Partner on Commercialization of FDA-Cleared DuraGraft
16 Apr 2024 //
GLOBENEWSWIRE
Qualigen Therapeutics` Direct Pan-RAS Inhibitors Presented at AACR 2024
10 Apr 2024 //
GLOBENEWSWIRE
Qualigen Announces Early Clinical Findings at the AACR
09 Apr 2024 //
GLOBENEWSWIRE
Qualigen Therapeutics Provides Corporate Update for Third Quarter
14 Nov 2023 //
GLOBENEWSWIRE
Qualigen Announces First Patient Dosed in the Phase 1a Trial of QN-302
07 Nov 2023 //
GLOBENEWSWIRE
Poster Highlighting Qualigen`s Pan-RAS Inhibitor Platform Presented at AACR
23 Oct 2023 //
GLOBENEWSWIRE
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR
27 Sep 2023 //
GLOBENEWSWIRE
Qualigen Therapeutics Partners with TD2 for Phase 1 Development of QN-302
17 Aug 2023 //
GLOBENEWSWIRE
Qualigen Reports Financial Results for Quarter Ending June 30, 2023
15 Aug 2023 //
GLOBENEWSWIRE
Qualigen Announces US FDA IND Clearance to Initiate Phase 1 Trial of QN-302
01 Aug 2023 //
GLOBENEWSWIRE
Qualigen Therapeutics Divests FastPack® Diagnostics Business
24 Jul 2023 //
GLOBENEWSWIRE
Poster Highlighting Qualigen Therapeutics™ Pan-RAS Inhibitor Platform Presented
05 Jun 2023 //
GLOBENEWSWIRE
Qualigen Therapeutics Reports FYR & Corporate Update for Quarter Ending 2023
16 May 2023 //
GLOBENEWSWIRE
Qualigen Pan-RAS Inhibitor Program Highlighted in (ASCO) 2023 Annual Meeting
02 May 2023 //
GLOBENEWSWIRE
Qualigen Reports Fourth Quarter and Year-End 2022 FYR
02 May 2023 //
GLOBENEWSWIRE
Qualigen Receives Nasdaq Notice Regarding Delayed Form 10-K Filing
21 Apr 2023 //
GLOBENEWSWIRE
Qualigen Presents Data On QN-247 in Triple Negative Breast Cancer at (AACR
18 Apr 2023 //
GLOBENEWSWIRE
Qualigen Therapeutics Announces Four Posters on QN-302
18 Apr 2023 //
GLOBENEWSWIRE
Composition of Matter Patent for QN-302 Granted by United States Patent Office
21 Mar 2023 //
GLOBENEWSWIRE
Qualigen to Present Posters at American Association for Cancer Research Meeting
15 Mar 2023 //
GLOBENEWSWIRE
Qualigen Therapeutics Presents Data on its RAS Inhibitor Program
09 Mar 2023 //
GLOBENEWSWIRE
Data on Biomarker for Qualigen Therapeutics Lead Program QN-302 Published
08 Mar 2023 //
GLOBENEWSWIRE
Qualigen Chief Executive Officer Michael Poirier Provides Letter to Stockholders
01 Feb 2023 //
GLOBENEWSWIRE
Qualigen Therapeutics Initiates GLP Toxicology Studies on QN-302
24 Jan 2023 //
GLOBENEWSWIRE
Qualigen Therapeutics Promotes Benedict M. Abugan to Vice President
23 Jan 2023 //
GLOBENEWSWIRE
Qualigen Therapeutics Receives Orphan Drug Designation from FDA for QN-302
10 Jan 2023 //
GLOBENEWSWIRE
Qualigen Therapeutics Provides Update on Developments at NanoSynex
05 Jan 2023 //
GLOBENEWSWIRE
Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
12 Dec 2022 //
GLOBENEWSWIRE
Qualigen Announces Pre-IND Feedback from USFDA Regarding QN-302
07 Dec 2022 //
GLOBENEWSWIRE
Qualigen Therapeutics, Inc. Reports Third Quarter 2022 Financial Results
15 Nov 2022 //
GLOBENEWSWIRE
Qualigen Announces Two Posters of RAS-Targeted Inhibitor Program
19 Oct 2022 //
GLOBENEWSWIRE
Qualigen Therapeutics to Present at LD Micro Main Event XV
18 Oct 2022 //
GLOBENEWSWIRE
Qualigen to Present Two Posters at the National Cancer Institute
06 Oct 2022 //
GLOBENEWSWIRE
Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer
14 Sep 2022 //
GLOBENEWSWIRE
Qualigen Announces Formation & First Meeting of QN-302 Scientific Advisory Board
18 Aug 2022 //
GLOBENEWSWIRE
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results
16 Aug 2022 //
GLOBENEWSWIRE
Qualigen Therapeutics Reports Positive QN-247 Readout in TNBC
01 Aug 2022 //
GLOBENEWSWIRE
Qualigen, Hande Sciences Partner to Scale-Up Mfg. for IND-Enabling Studies
06 Jul 2022 //
CONTRACTPHARMA
Qualigen Therapeutics Announces Partnership with Hande Sciences for QN-302
06 Jul 2022 //
GLOBENEWSWIRE
Qualigen Therapeutics to Present at BIO International Convention
14 Jun 2022 //
GLOBENEWSWIRE
Qualigen Announces IND-Enabling Studies to Advance Lead Program QN-302
07 Jun 2022 //
GLOBENEWSWIRE
Qualigen Therapeutics Acquires Majority Stake in NanoSynex
02 Jun 2022 //
GLOBENEWSWIRE
Qualigen Therapeutics` Pan-RAS Inhibitor Featured in Two Abstracts at ASCO
26 May 2022 //
GLOBENEWSWIRE
Qualigen to Present at the H.C. Wainwright Global Investment Conference
20 May 2022 //
GLOBENEWSWIRE
Qualigen Reports First Quarter 2022 Financial Results
13 May 2022 //
GLOBENEWSWIRE
Qualigen Therapeutics Partner NanoSynex to Present Technology at BioMed Israel
10 May 2022 //
GLOBENEWSWIRE
Qualigen to Acquire Majority Stake in Diagnostics Technology Company NanoSynex
03 May 2022 //
GLOBENEWSWIRE
Qualigen Appoints Shishir Sinha to Lead Diagnostics Division
29 Apr 2022 //
GLOBENEWSWIRE
Qualigen Therapeutics Presents Three Posters of QN-302 at AACR
12 Apr 2022 //
GLOBENEWSWIRE
Qualigen Tx Resumes WW Distribution and Commercial Control Over FastPack®
05 Apr 2022 //
GLOBENEWSWIRE
Qualigen Therapeutics, Inc. Reports Year-End 2021 Financial Results
01 Apr 2022 //
GLOBENEWSWIRE
Qualigen Engages TD2 as CRO for Preclinical Development of QN-302
30 Mar 2022 //
GLOBENEWSWIRE
Qualigen Tx Announces Three Published Abstracts at AACR
22 Mar 2022 //
GLOBENEWSWIRE
